Exploring new treatments for aggressive brain tumors
Strategies for the Development of Multimodal Therapies in Tumors of the Central Nervous System: Identification of New Molecular and Metabolic Targets Implicated in Survival and Chemoresistance Involving Endothelial and Cancer Stem Cells
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT06348693
This study is trying to find new treatments for aggressive brain tumors by looking at how certain cancer cells behave in low-oxygen environments and how they respond to current therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT06348693 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on glioblastoma and glioma, investigating the role of cancer stem cells (CSCs) in tumor aggressiveness and resistance to current therapies. It aims to understand how the hypoxic tumor microenvironment influences CSC behavior and their response to treatment. By isolating cells from tumor biopsies and examining biomarkers, the study seeks to uncover potential therapeutic targets related to sphingolipids and their metabolic pathways. The findings could lead to more effective treatment strategies for patients with these challenging brain tumors.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed glioma undergoing surgical resection.
Not a fit: Patients who do not provide informed consent or those without a confirmed diagnosis of glioma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic approaches that improve outcomes for patients with glioblastoma and glioma.
How similar studies have performed: While there is ongoing research into cancer stem cells and their role in glioblastoma, this specific approach focusing on the hypoxic microenvironment and sphingolipid pathways is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with glioma diagnosed histologically confirmed (WHO) undergoing surgical resection; * hypomethylation or hypermethylation of MGMT assessed post-surgery for patients affected by GBM; * adult patients (≥18 years), both sexes; * Patients undergoing Stupp protocol including patients aged \> 70 years performing the hypofractionated protocol and three weeks of chemotherapy; * Karnofsky Performance Status (KPS)\> 60 assessed post-surgery; * freely given written informed consent prior to any activity related to the study. erine Exclusion Criteria: * patients who do not sign the informed consent
Where this trial is running
Milan
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Stefania E Navone, PhD — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Study coordinator: Stefania E Navone, PhD
- Email: stefania.navone@policlinico.mi.it
- Phone: 0255034268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioblastoma, Glioma, Glioma Glioblastoma Multiforme, cancer stem cells, tumor endothelial cells, sphingolipids, sphingosine-1-phosphate, platelets